At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 24, 2026 at 16:47 ET
Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with enhanced change-in-control severance (2x base + bonus, 18-month COBRA, full equity vesting), (2) bylaw amendments adding universal proxy rules, a formal 'Cause' definition, and an emergency CEO/CFO succession framework, and (3) annual meeting results including approval of a reverse stock split (ratio up to 1:250) and ratification of Baker Tilly as auditor. The $4M micro-cap's board is entrenching governance provisions and increasing executive golden parachutes as the company appears to prepare for potential restructuring or a sale process.
- CEO James Rolke and CFO Chester Zygmont III entered new 3-year employment agreements with 2x base + target bonus change-in-control severance (up from 1x), plus 18-month COBRA and full equity acceleration
- Stockholders approved a reverse stock split at any ratio between 1:2 and 1:250, within one year, with no further stockholder vote required
- Bylaws amended to add a formal 'Cause' definition (requiring independent-board determination) and emergency succession for CEO/CFO vacancies
- Annual meeting votes: 519,169 for Jennifer Carver as Class A director (vs 24,779 against, 263,081 withheld); 1,786,623 for reverse split authorization
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access